Quantity and function of high density lipoprotein as an indicator of coronary atherosclerosis

Journal of the American College of Cardiology

Volumn 33, Issue 2, 1999, Pages 436-443

  Saku, Keijiro ^a   Zhang, Bo ^a   Ohta, Takao ^b   Arakawa, Kikuo ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF THE RYUKYUS SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; CORRELATION FUNCTION; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; ULTRACENTRIFUGATION;

EID: 0033081744     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00560-9     Document Type: Article

References (46)

1. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79:1989;8-15.
2. Gordon D.J., Rifkind B.M. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med. 321:1989;1311-1316.
3. Tall A.R. An overview of reverse cholesterol transport. Eur Heart J. 19:1998;A31-A35.
4. Paszty C., Maeda N., Verstuyft J., Rubin E.M. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 94:1994;899-903.
5. Rubin E.M., Krauss R.M., Spanler E.A., Verstuft J.G., Clift S.M. Inhibition of early atherosclerosis in transgenic mice by human apolipoprotein AI. Nature. 353:1991;265-266.
6. Plump A.S., Scott C.J., Breslow J.L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA. 91:1994;9607-9611.
7. Plump A.S., Erickson S.K., Weng W., Partin J.S., Breslow J.L., Williams D.L. Apolipoprotein A-I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production. (see comments) J Clin Invest. 97:1996;2660-2671.
8. Dobiasova M., Frohlich J.J. Structural and functional assessment of high-density lipoprotein heterogeneity. Clin Chem. 40:1994;1554-1558.
9. Brook J.G., Aviram M., Viener A., Shilansky E., Markiewicz W. High-density lipoprotein subfractions in normolipidemic patients with coronary atherosclerosis. Circulation. 66:1982;923-926.
10. Stampfer M.J., Sacks F.M., Salvini S., Willett W.C., Hennekens C.H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 325:1991;373-381.
11. Dobiasova M., Stribrna J., Sparks D.L., Pritchard P.H., Frohlich J.J. Cholesterol esterification rate in very low density lipoprotein- and low density lipoprotein-depleted plasma. Relation to high density lipoprotein subspecies, sex, hyperlipidemia, and coronary artery disease. Arterioscler Thromb. 11:1991;64-70.
12. Shepherd J., Packard C.J. High density lipoprotein metabolism. Catapano A.L., Bernini F., Corsini A., Atherosclerosis Reviews (Vol. 24). 1993;17-41 Raven Press, New York.
13. Johnson W.J., Mahlberg F.H., Rothblat G.H., Phillips M.C. Cholesterol transport between cells and high-density lipoproteins. Biochim Biophys Acta. 1085:1991;273-298.
14. Small D.M. HDL system a short review of structure and metabolism. Catapano A.L., Salvioli G., Vergani C., Atherosclerosis Reviews (Vol. 16). 1987;1-8 Raven Press, New York.
15. Fielding C.J., Fielding P.E. Molecular physiology of reverse choesterol transport. J Lipid Res. 36:1995;211-228.
16. Kunitake S.T., Mendel C.M., Hennessy L.K. Interconversion between apolipoprotein A-I-containing lipoproteins of prebeta and alpha electrophoretic mobilities. J Lipid Res. 33:1992;1807-1816.
17. Tsujita M., Yokoyama S. Selective inhibition of free apolipoprotein-mediated cellular lipid efflux by probucol. Biochemistry. 35:1996;13011-13020.
18. Oram J.F., Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res. 37:1996;2473-2491.
19. Mendez A.J. Cholesterol efflux mediated by apolipoproteins is an active cellular process distinct from efflux mediated by passive diffusion. J Lipid Res. 38:1997;1807-1821.
20. Brown M.L., Inazu A., Hesler C.B., et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature. 342:1989;448-451.
21. Inazu A., Brown M.L., Hesler C.B., et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 323:1990;1234-1238.
22. Hill S.A., McQueen M.J. Reverse cholesterol transport - a review of the process and its clinical implications. Clin Biochem. 30:1997;517-525.
23. Judkins M.P. A percutaneous transfemoral technique. Radiology. 89:1967;815-821.
24. Saku K., Jimi S., Sasaki N., et al. Reduced coronary vasodilation in patients with familial hypercholesterolemia following intracoronary injection of isosorbide dinitrate. Jpn Circ J. 59:1995;808-814.
25. 2+, and an anion-exchange resin. Clin Chem. 24:1978;1504-1508.
26. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 34:1955;1345-1353.
27. Ikeda T., Shibuya U., Sugiuchi H., Araki S., Uji Y., Okabe H. Automated immunoturbidimetric analysis of six plasma apolipoproteins correlation with radioimmunodiffusion assays. J Clin Lab Anal. 5:1991;90-95.
28. Abe A., Maeda S., Makino K., et al. Enzyme-linked immunosorbent assay of lipoprotein(a) in serum and cord blood. Clin Chim Acta. 177:1988;31-40.
29. Ohta T., Saku K., Takata K., Nakamura R., Ikeda Y., Matsuda I. Different effects of subclasses of HDL containing apo A-I (LpA-I) on cholesterol esterification in plasma and net cholesterol efflux from foam cells. Arterioscler Thromb Vasc Biol. 15:1995;956-962.
30. SAS/STAT User's Guide, Version 6, Volume 2. 4th ed. Cary, NC: SAS Institute Inc., 1990:891-1456.
31. SAS Procedures Guide, Version 6. 3rd ed. Cary, NC: SAS Institute Inc., 1990:209-634.
32. Anderson J.L., King G.J., Thomson M.J., et al. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol. 30:1997;1206-1211.
33. Nakauchi Y., Suehiro T., Yamamoto M., et al. Significance of angiotensin I-converting enzyme and angiotensin II type 1 receptor gene polymorphisms as risk factors for coronary heart disease. Atherosclerosis. 125:1996;161-169.
34. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. (see comments) N Engl J Med. 335:1996;1001-1009.
35. 3 subclasses study in hypertensive and normal middle-aged and septuagenarian men. J Lipid Res. 33:1992;1411-1418.
36. Marotti K.R., Castle C.K., Boyle T.P., Lin A.H., Murray R.W., Melchior G.W. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 364:1993;73-75.
37. Tall A., Granot E., Brocia R., et al. Accelerated transfer of cholesteryl esters in dyslipidemic plasma. Role of cholesteryl ester transfer protein. J Clin Invest. 79:1987;1217-1225.
38. Inazu A., Koizumi J., Mabuchi H., Kajinami K., Takeda R. Enhanced cholesteryl ester transfer protein activities and abnormalities of high density lipoproteins in familial hypercholesterolemia. Horm Metab Res. 24:1992;284-288.
39. Bagdade J.D., Ritter M.C., Subbaiah P.V. Accelerated cholesteryl ester transfer in patients with insulin-dependent diabetes mellitus. Eur J Clin Invest. 21:1991;161-167.
40. Barter P.J., Rye K.A. Molecular mechanisms of reverse cholesterol transport. Curr Opin Lipidol. 7:1996;82-87.
41. Yokoyama S. Apolipoprotein-mediated cellular cholesterol efflux. Biochim Biophys Acta. 1392:1998;1-15.
42. Parthasarathy S., Barnett J., Fong L.G. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta. 1044:1990;275-283.
43. Cockerill G.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 15:1995;1987-1994.
44. Schlesselman J.J. Case-Control Studies-Design, Conduct, Analysis. 1982;1-346 Oxford University Press, London.
45. Pearson T.A., Derby A.A. Invited commentary should arteriographic case-control studies be used to identify causes of atherosclerotic coronary artery disease? Am J Epidemiol. 134:1991;123-128.
46. Ambrose J.A., Fuster V. Can we predict future acute coronary events in patients with stable coronary artery disease? (editorial comment) JAMA. 277:1997;343-344.